Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas

Tumori

Volumn 94, Issue 5, 2008, Pages 674-680

  Yaman, Emel ^a   Buyukberber, Suleyman ^a   Uner, Aytug ^a   Coskun, Ugur ^a   Yamac, Deniz ^a   Ozturk, Banu ^a   Kaya, Ali Osman ^a   Yildiz, Ramazan ^a   Beneklifor, Mustafa ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Carboplatin; Cyclophosphamide; Malignant gliomas; Temozolomide refractory

Indexed keywords

CARBOPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; TEMOZOLOMIDE;

ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 56749085822     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400505     Document Type: Article

References (43)

1. Soffietti R, Rudà R, Trevisan E: New chemotherapy options for the treatment of malignant gliomas. Anti-cancer Drugs, 18: 621-631, 2007.
2. Buckner JC: Factors influencing survival in high grade gliomas: Semin Oncol, 30 (Suppl 19): 10-14, 2003.
3. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs procarbazine in patients with glioblastoma at first relapse. Br J Cancer, 83: 588-593, 2000.
4. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol, 12: 259-266, 2001.
5. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol, 17: 2762-2771, 1999.
6. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol, 2: 552-560, 2001.
7. Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first line temozolomide chemotherapy: A phase II study of the Gruppo Italiona Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol, 22: 4779-4786, 2004.
8. Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC, Heimans JJ: PVC chemotherapy for recurrent glioblastoma multiforme. Neurology, 56: 118-120, 2001.
9. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma. J Clin Oncol 23: 9359-9369, 2005.
10. Dresemann G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol, 16: 1702-1706, 2005.
11. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA: Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol, 83: 53-60, 2007.
12. Raizer JJ: HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neuro-Oncol, 74: 77-86, 2005.
13. Rich JN, Reardon DA, Peery T Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS: Phase II study of gefitinib in recurrent glioblastoma. J Clin Oncol, 22: 133-142, 2004.
14. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 15: 1253-1259, 2007.
15. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol, 25: 4722-4729, 2007.
16. Poisson M, Pereon Y, Chiras J, Delattre JY: Treatment of recurrent malignant supratentorial gliomas with carboplatin. J Neurooncol, 10: 139-144, 1991.
17. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol, 10: 1074-1077, 1992.
18. Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent glioma: a phase II study. J Clin Oncol, 9: 860-864, 1991.
19. Stein ME, Kuten A, Drumea K, Goldsher D, Tzuk-Shina Z: Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure. A clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol, 71: 167-170, 1999.
20. Watanebe K, Kanaya H, Fujiyama Y, Kim P: Combination chemotherapy using carboplatin (JM-8) and etoposide (JET) chemotherapy for recurrent malignant gliomas: A Phase II study. Acta Neurochir, 144: 1265-1270, 2002.
21. Viñolas N, Gil M, Verger E, Villá S, Pujol T, Ceral L, García M, Graus F: Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs, 13: 163-167, 2002.
22. Chamberlain M, Tsao-Wei DD: Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer, 100: 1213-1220, 2004.
23. Kleihues P, Cavenee WK (Eds): Pathology and genetics of tumors of the nervous system: In: World Health Organization Classification of the Tumors of the Nervous system, Editorial and Consensus Conference Working Group. IARC Press, Lyon, 2000.
24. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
25. National Cancer Institute Toxicity Criteria Version 3.0 ctep.cancer.gov/forms/CTCAEv3.pdf.Nervous System Consortium.
26. Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, Piantadosi S: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol, 15: 3121-3128, 1997.
27. Kuhn JG: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntingt), 16: 33-40, 2002.
28. Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, Gajjar A: Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res, 8: 2202-2209, 2002.
29. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomas. N Engl J Med, 352: 987-997, 2005.
30. Ammirati M, Galicich JH, Arbit E, Liao Y: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery, 21: 607-614, 1987.
31. Harsh GR 4th, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery, 21: 615-621, 1987.
32. Dirks P, Bernstein M, Muller PJ, Tucker WS: The value of reoperation for recurrent glioblastoma. Can J Surg, 36: 271-275, 1993.
33. Chamberlain MC, Barba D, Kormanik P, Shea WM: Stereotactic radiosurgery for recurrent gliomas. Cancer, 74: 1342-1347, 1994.
34. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L: The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys, 2005, 63: 47-55, 2005.
35. Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM: Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther, 321: 265-275, 2007.
36. Caroli M, Locatelli M, Campanella R, Motta F, Mora A, Prada F, Borsa S, Martinelli-Boneschi F, Saladino A, Gaini SM: Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J Neurooncol, 84: 71-77, 2007.
37. Brandes AA, Pasetto LM, Vastola F, Monfardini S: Temozolomide in patients with high-grade glioma. Oncology, 59: 181-186, 2000.
38. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M: Gruppo Italiano Cooperativo di Neuro-Oncologia. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a pahse ii study of the Gruppo Italiano Cooperativo di Neuro-Oncologica. J Clin Oncol, 22: 1598-1604, 2004.
39. Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, Boiardi A: Phase II trial of cisplatin plus temozolomide in recurrent and progressive malignant glioma patients. J Neuroncol, 66: 203-208, 2004.
40. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L: Chemotherapy response criteria in malignant glioma. Neurology, 48: 1336-1340, 1997.
41. Walker MD, Green SB, Byar DP, Alexander E Jr, Betzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomised comparison of radiotherapy and nitrosureas for the treatment of malignant gliomas after surgery. N Engl J Med, 303: 1323-1329, 1980.
42. Dinapoli RP, Brown LD, Arusell RM, Earle JD, O'Fallon JR, Buckner JC, Scheithauer BW, Krook JE, Tschetter LK, Maier JA: Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol, 11: 1316-1321, 1993.
43. Elliott TE, Dinapoli RP, O'Fallon JR, Krook JE, Earle JD, Morton RF, Levitt R, Tschetter LK, Scheithauer BW, Pfeifle DM, Twito DI, Nelimark RA: Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high-grade astrocytoma. J Neurooncol, 33: 239-250, 1997.